ASSOCIATION OF COMMUNITY CANCER CENTERS This content is provided for informational purposes only and is not meant to substitute for medical advice, diagnosis, or treatment purposes. ACCC does not endorse or recommend any specific prescription drug or any other information in this publication. The programs represented herein have been set up primarily by drug companies that offer free or low-cost drugs to insured, uninsured, or underinsured individuals who cannot afford their medication. Companies offer these programs voluntarily, and the government does not require the provision of free medicine. All content and links reflect accuracy on this date. The ACCC Patient Assistance & Reimbursement Guide was updated starting March 1, 2021 and published online in April 2021. This publication is updated four times a year. Visit accc-cancer.org/PatientAssistanceGuide to download and print the most up-to-date information on cancer drug assistance and reimbursement programs. 2021 PATIENT ASSISTANCE & REIMBURSEMENT GUIDE 1 A Message from Jorge J. Garcia PharmD, MS, MHA, MBA, FACHE, ACCC Board of Trustees Member and OPEN Advisory Committee Member This year ACCC is proud to publish the 10th print edition of its Patient Assistance & Reimbursement Guide. ACCC Immediate-Past President Ali McBride, PharmD, MS, BCOP, shared with us last year how cancer pro- grams and practices across the nation have expanded their financial advocacy efforts to include pharmacy and other supportive care staff as part of this critical patient service. Recognizing that our financial naviga- tion and pharmacy members are both “super-users” of this guide and the front-line staff responsible for helping patients with cancer overcome financial toxicity, ACCC made a thoughtful decision to more closely align its Patient Assistance & Reimbursement Guide with the ACCC Financial Advocacy Network (FAN) and the ACCC Oncology Pharmacy Education Network (OPEN). Leveraging color and branding—note the purple and orange hues long associated with the ACCC financial advocacy and pharmacy initiatives—and content, this year’s guide highlights the power of multidisciplinary care and the passion that cancer care teams have for treating our patients’ mind, body, and spirit. As we head into a new year, we must also learn from our experiences in 2020 with the COVID-19 public health emergency. The impact of this pandemic is felt across all walks of life, especially among our frontline workers and our patients with cancer. Not only are our patients considered an at-risk population for getting COVID-19, but the country’s economic downturn as a result of the worldwide pandemic has taken a serious toll on these patients—regardless of their insurance coverage status. Many of our patients have lost their jobs and/or healthcare coverage, and they need financial assistance now more than ever. I want to take this time to thank all the financial navigators, financial counselors, pharmacy staff, social workers, and anyone else who has helped their patients receive the financial assistance they need. For those new to financial advocacy, ACCC has updated its patient assistance flowchart (page 14) and developed a practical, step-by-step instruction to guide you as you help your patients access and pay for their cancer therapies. The article (pages 7-13) features members features members of the ACCC Financial Advocacy Network, who shared with us their experiences and workflows to help guide those new to finan- cial navigation. I am also excited to share that ACCC has been hard at work looking to the future of this resource and how to best meet the changing needs of its members. Specifically, ACCC is exploring ways to create a robust and user-friendly digital Patient Assistance & Reimbursement Guide as a companion piece to the annual print edition—more news to come on this in 2021. As the pace of drug approvals and the addition of novel agents increase exponentially, continual education and learning are needed. To help in this effort, the Patient Assistance & Reimbursement Guide is updated on a quarterly basis with the most updated information on cancer drug assistance and reimbursement programs, including directions on how to apply and links to enrollment forms. But we want your help! As you use this guide throughout the year, if you know of any changes, updates, and/or corrections to the information within, let us know. Please direct all comments, questions, comments, and feedback to Maddelynne Parker at [email protected]. 2021 PATIENT ASSISTANCE & REIMBURSEMENT GUIDE 1 ASSOCIATION OF COMMUNITY CANCER CENTERS 1 A Message from Dr. Jorge J. Garcia, ACCC Board of Trustees Member and OPEN Advisory Committee Member 9 Fighting Financial Toxicity: How Financial Navigators Help Patients with All Insurance Types By Teri Brown; Aimee Hoch, LSW; Jordan Karwedsky; Jennifer Paquet, RN, BSN; and Jeanie Troy 16 Financial Navigation Flowchart Pharmaceutical Company Patient Sanofi Genzyme 85 Assistance & Reimbursement Programs Seagen 87 AbbVie, Inc. 17 Sun Pharmaceutical Industries, Inc. 88 Amgen, Inc. 18 Taiho Oncology 90 Astellas Pharma U.S., Inc. 20 Takeda Oncology 92 AstraZeneca 23 TerSera Therapeutics 94 Bayer HealthCare Pharmaceuticals, Inc. 25 Teva Oncology 95 BeiGene 29 Blueprint Medicines 30 Medical Device & Testing Patient Bristol Myers Squibb 32 Assistance & Reimbursement Programs Celgene Oncology 34 Adaptive Biotechnologies 98 Coherus BioSciences 36 Foundation Medicine 100 Daiichi Sankyo 37 Other Patient Assistance Programs & Resources Daiichi Sankyo and AstraZeneca 39 Agingcare.com® 104 Eisai Co., Ltd. 41 AuntBertha.com 104 Eli Lilly and Company 43 BenefitsCheckUp® 104 EMD Serono, Inc. 46 Epizyme, Inc. 48 CancerCare® 104 Exelixis, Inc. 50 Cancer Financial Assistance Coalition 105 Genentech, Inc. 51 Co-Pay Relief 105 GlaxoSmithKline 53 FamilyWize® 106 G1 Therapeutics 55 Good Days® 106 Immunomedics 56 HealthWell Foundation® 107 Incyte Corporation 57 The Leukemia & Lymphoma Society 107 Ipsen Biopharmaceuticals, Inc. 59 Medicine Assistance Tool 108 Janssen Biotech, Inc. 61 NeedyMeds 108 Jazz Pharmaceuticals 63 Patient Access Network Foundation 109 Karyopharm Therapeutics 64 Patient Advocate Foundation 109 Kite Pharma 66 RxAssist 110 Merck 67 MorphoSys 69 RxHope™ 108 Mylan 71 Rx Outreach® 110 Novartis Pharmaceuticals Corporation 73 Quick Reference Guide 114 Oncopeptides 75 Pfizer, Inc. 77 Pharmacyclics, LLC 79 The ACCC Patient Assistance & Reimbursement Guide was printed in January 2021. This publication is updated four times a year. Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme 81 Visit accc-cancer.org/PatientAssistanceGuide to download and Sandoz 83 print the most up-to-date information on cancer drug assistance and reimbursement programs. 2 ASSOCIATION OF COMMUNITY CANCER CENTERS 2021 PATIENT ASSISTANCE & REIMBURSEMENT GUIDE 3 Patient Assistance & Reimbursement Erivedge® (vismodegib) capsules 51 Assistance Programs Erwineaze® (asparaginase Erwinia chrysanthemi) for injection 63 Exjade® (deferasirox) tablets for oral suspension 73 by drug or product Faslodex® (fulvestrant) injection 23 Abraxane® (paclitaxel protein-bound particles Femara® (letrozole) tablets 73 for injectable suspension) (albumin-bound) 34 Fulphila® (pegfilgrastim-jmdb) injection 71 Adakveo® (crizanlizumab-tmca) for IV infusion 73 Gardasil®9 (Human Papillomavirus 9-valent Adcetris® (brentuximab vedotin) for injection 87 Vaccine, Recombinant) 67 Afinitor® (everolimus) tablets 73 Gavreto™ (pralsetinib) capsules 30 Alecensa® (alectinib) capsules 51 Gazyva® (obinutuzumab) injection 51 Alimta® (pemetrexed) for injection 43 Gleevec® (imatinib mesylate) tablets 73 Aliqopa™ (copanlisib) for injection 25 Granix® (tbo-filgrastim) injection 95 Alunbrig® (brigatinib) tablets 92 Halaven® (eribulin mesylate) injection 41 Aranesp® (darbepoetin alfa) injection 18 Herceptin® (trastuzumab) injection for intravenous use 51 Aromasin® (exemestane) tablets 77 Herceptin Hylecta™ (hyaluronidase-oysk) injection 51 Avastin® (bevacizumab) injection for IV use 51 Herzuma® (trastuzumab-pkrb) for injection 95 Ayvakit™ (avapritinib) tablets 30 Ibrance® (palbociclib) capsules 77 Balversa™ (erdafitinib) tablets 61 Iclusig® (ponatinib) tablets 92 Bavencio® (avelumab) injection 46 Idamycin® (idarubicin hydrochloride) injections 77 Bendeka® (bendamustine HCI) injection 95 Idhifa® (enasidenib) tablets 34 Besponsa® (inotuzumab ozogamicin) injection for IV infusion 77 Imbruvica® (ibrutinib) capsules 79 Blenrep (belantamab mafodotin-blmf) for injection 53 Imfinzi® (durvalumab) injection for intravenous use 23 Blincyto® (blinatumomab) for injection 18 Imlygic® (talimogene laherparepvec) suspension Bosulif® (bosutinib) tablets 77 for injection 18 Braftovi® (encorafenib) capsules 77 Inlyta® (axitinib) tablets 77 ™ Brukinsa (zanubrutinib) capsules 29 Inqovi®(decitabine and cedazuridine) tablets 90 Cabometyx® (cabozantinib) tablets 50 Inrebic® (fedratinib) capsules 34 Calquence® (acalabrutinib) capsules 23 Intron® A (interferon alfa-2b, recombinant) Camptosar® (irinotecan hydrochloride) injection 77 for injection 67 Cometriq® (cabozantinib) capsules 50 Iressa® (gefitinib) 23 Cosela™ (trilaciclib) for injection 55 Istodax® (romidepsin) for injection 34 Cotellic® (cobimetinib) tablets 51 Jadenu® (deferasirox) tablets 73 Cyramza® (ramucirumab) injection 43 Jakafi® (ruxolitinib) tablets 57 Darzalex® (daratumumab) injection for intravenous infusion 61 Jevtana® (cabazitaxel) injection 85 Darzalex Faspro™ (daratumumab and hyaluronidase-fihj) Kadcyla® (ado-trastuzumab emtansine)